Time filter

Source Type

Dietrich A.,University of Leipzig | Bouzidi M.,Kliniken der Stadt Cologne | Hartwig T.,Parkkrankenhaus Leipzig | Schutz A.,Institute for Pathology Elsapark | Jonas S.,University of Leipzig
Archives of Gynecology and Obstetrics | Year: 2012

Purpose Rapamycin, an immunosuppressive in transplant surgery, has an additional antiproliferative effect. The aim of this study was to investigate the potential protective effects of rapamycin on postoperative adhesion development. Methods Ten rats per group underwent midline incision laparotomy and adhesion induction including bowel sutures. Therapy groups received daily intraperitoneal rapamycin injections (1.5 mg/kg body weight) for 3 weeks postopera-tively. Controls were rats without any postoperative treatment, rats receiving the rapamycin solvent or a hyaluronic TM acid-carboxymethylcellulose membrane (Seprafilm™). Results Postoperative rapamycin application led to enhanced adhesion development and there was a higher TM rate of wound infections. In addition, Seprafilm™ did not reduce adhesions, in subgroups there were even more. Conclusions Rapamycin is not recommendable for perioperative immunosuppression, it enhances adhesion development and leads to a higher rate of wound TM infections. Surprisingly, the established Seprafilm™ membrane led to more adhesions in our experimental setting. © 2012 Springer-Verlag. Source

Sequelae of facial palsy are often underdiagnosed. The ophthalmologist plays a pivotal role in the acute, subacute and chronic treatment of this condition. Goals are to provide corneal protection, restoration of facial asymmetry and facial movements and the treatment of crocodile tears. Botulinum toxin is the first line treatment for sequelae due to aberrant regeneration. The indications and techniques for treatment with botulinum toxin in patients with facial palsy are presented. © 2012 Springer-Verlag. Source

Ilko D.,University of Wurzburg | Steiger C.,University of Wurzburg | Keller R.,Kliniken der Stadt Cologne | Holzgrabe U.,University of Wurzburg | Meinel L.,University of Wurzburg
European Journal of Pharmaceutics and Biopharmaceutics | Year: 2016

Counterfeit drugs are a major threat to public health. Current efforts focus on serialization of the secondary packaging which do not allow to trace the individual unit. As a proof of concept, we intended to mark each tablet for its unambiguous recognition. Spiking monodisperse PEGs into tablet coating solutions at concentrations as low as 3 ppm was instrumental to "write" a code into each tablet film which was readily read upon isolation and LC-MS/MS analysis. Different qualities and amounts of monodisperse polyethylene glycols can be used for coding solid drug products. The approach is limited to cases in which PEGs are not present for formulation purposes as excipients, as coding against this background was unfeasible. © 2015 Elsevier B.V. All rights reserved. Source

Buhren K.,RWTH Aachen | Schwarte R.,RWTH Aachen | Fluck F.,RWTH Aachen | Timmesfeld N.,University of Marburg | And 6 more authors.
European Eating Disorders Review | Year: 2014

Objective Patients with anorexia nervosa (AN) exhibit high rates of psychiatric comorbidity. To disentangle the effects of duration of illness on comorbid psychiatric symptoms, we investigated the rates of comorbid psychiatric disorders, suicidality and self-harm behaviour in adolescent patients with a first onset of AN. Methods In adolescent females (n = 148) with a first onset of AN, body mass index, psychiatric comorbidity (according to DSM-IV), depressive symptoms, suicidality and self-injurious behaviour were assessed. Results Seventy patients (47.3%) met the criteria for at least one comorbid psychiatric disorder. The binge-purging subtype was associated with increased rates of psychiatric comorbidity, suicidality and self-injurious behaviour. The severity of eating disorder-specific psychopathology influenced current psychiatric comorbidity and suicidal ideation. Conclusion Prevalence rates of comorbid psychiatric disorders and suicidal ideation are considerably lower among adolescents with AN compared with adults. An early and careful assessment, along with adequate treatment of the eating disorder, might prevent the development of severe psychiatric comorbidities. Copyright © 2013 John Wiley & Sons, Ltd and Eating Disorders Association. Copyright © 2013 John Wiley & Sons, Ltd and Eating Disorders Association. Source

Focker M.,University of Duisburg - Essen | Buhren K.,RWTH Aachen | Timmesfeld N.,University of Marburg | Dempfle A.,University of Marburg | And 8 more authors.
European Child & Adolescent Psychiatry | Year: 2014

Body mass index (BMI) is one of the most important outcome predictors in patients with anorexia nervosa (AN). A low premorbid BMI percentile calculated by the patients recalled premorbid weight and the height at first admission has been found to predict the BMI at first inpatient admission. In this study, we sought to confirm this relationship. We additionally analyze the relationship between premorbid BMI percentile and BMI percentile at discharge from the first inpatient treatment and at 1-year follow-up or alternatively if applicable upon readmission within this time period. We included 161 female patients aged 11-18 years of the multisite ANDI-trial with a DSM-IV diagnosis of AN. We used a multivariate statistical model including the independent variables age, duration of illness, duration of treatment, BMI at admission and BMI percentile at discharge. The relationship between premorbid BMI percentile and BMI at admission was solidly confirmed. In addition to premorbid BMI percentile, BMI at admission and age were significant predictors of BMI percentile at discharge. BMI percentile at discharge significantly predicted BMI percentile at 1-year follow-up. An additional analysis that merely included variables available upon referral revealed that premorbid BMI percentile predicts the 1-year follow-up BMI percentile. Further studies are required to identify the underlying biological mechanisms and to address the respective treatment strategies for AN patients with a low or high premorbid BMI percentile. © 2014 Springer-Verlag Berlin Heidelberg. Source

Discover hidden collaborations